Other languages Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Real-time Estimate Cboe BZX Other stock markets 09:49:00 2024-05-20 am EDT			5-day change	1st Jan Change
8.87 ^USD	0.00%		-0.90%	+9.93%

May. 13	Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 24	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge	Apr. 24
Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS	Apr. 24
Centessa Pharmaceuticals Eyes $100 Million in ADS Offering	Apr. 23
Centessa Pharmaceuticals plc Announces Open IND for ORX750	Apr. 22
Centessa Pharmaceuticals plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Centessa Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28
Centessa Pharmaceuticals Insider Sold Shares Worth $607,960, According to a Recent SEC Filing	Mar. 26
Centessa Pharmaceuticals plc Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2A Study of Serpinpc for the Treatment of Hemophilia	Dec. 10
AnaptysBio Secures Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio	Nov. 27
Anaptysbio, Inc. Enters into License Agreement with Centessa Pharmaceuticals (UK) Limited	Nov. 27
Centessa Pharmaceuticals' Q3 Loss Narrows	Nov. 13
Centessa Pharmaceuticals plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Centessa Pharmaceuticals plc Announces Dosing of First Subject in Registrational Present-3 Study Evaluating Serpinpc for the Treatment of Hemophilia B with Inhibitors	23-10-31
Centessa Pharmaceuticals plc Announces Preclinical Data Supporting Orx750's Potential as A Best-In-Class Oral Ox2r Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders	23-10-25
Centessa Pharmaceuticals plc Announces Executive Appointments	23-10-04
Centessa Pharmaceuticals Insider Sold Shares Worth $235,688, According to a Recent SEC Filing	23-09-22
World Sleep Congress Releases an Abstract Submit by Centessa Pharmaceuticals plc	23-08-24
Centessa Pharmaceuticals plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B Without Inhibitors	23-07-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Other languages

Filters